The vaccine was delivered to healthy volunteers via a single subcutaneous injection. Between 14 and 16 days after the dose, the mean level of patients' T cells generated in response to the company's hAd5 S+N T-cell vaccine was 10 times higher for N-specific T cells. By day 21, both S and N T-cell responses had achieved levels 10 times higher than prevaccination levels.

The mean T-cell levels seen in the vaccinated participants were equivalent to those for patients recovered from infection by the SARS-CoV-2 virus, the company reported.

Previously, ImmunityBio reported that T cells isolated from previously infected individuals react to the antigens delivered by the vaccine, indicating that immune responses to the vaccine could be protective against SARS-CoV-2 infection and COVID-19 illness.

ImmunityBio, NantKwest to begin mixed COVID-19 vaccine trial
The U.S. Food and Drug Administration (FDA) has authorized ImmunityBio and NantKwest to expand phase I testing of a bivalent human adenovirus 5 T-cell...

ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated...

ImmunityBio uses Microsoft software to visualize SARS-CoV-2 spike protein
ImmunityBio has released results from a molecular dynamics simulation, conducted in collaboration with Microsoft, that provided a visualization of the...

ImmunityBio, NantKWest to merge
ImmunityBio and NantKWest have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a new immunotherapy and...

ImmunityBio COVID-19 oral vaccine effective in nonhuman primates
ImmunityBio's COVID-19 vaccine candidate has been shown to protect nasal and lung airways of nonhuman primates against SARS-CoV-2 in preclinical studies.